Imagion Biosystems has lodged Appendix 3B: New issue announcement, application for quotation of additional securities and agreement.
View Appendix 3B.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal